Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response by unknown
ORIGINAL ARTICLE – COLORECTAL CANCER
Long-Term Outcome of Rectal Cancer With Clinically (EUS/
MRI) Metastatic Mesorectal Lymph Nodes Treated
by Neoadjuvant Chemoradiation: Role of Organ Preservation
Strategies in Relation to Pathologic Response
Claudio Belluco, MD, PhD1, Marco Forlin, MD1, Matteo Olivieri, MD1, Renato Cannizzaro, MD2,
Vincenzo Canzonieri, MD3, Angela Buonadonna, MD4, Ettore Bidoli, ScD5, Fabio Matrone, MD6, Giulio Bertola,
MD1, and Antonino De Paoli, MD6
1Department of Surgical Oncology, CRO–IRCCS, National Cancer Institute, Aviano, Italy; 2Department of
Gastroenterology, CRO–IRCCS, National Cancer Institute, Aviano, Italy; 3Department of Pathology, CRO–IRCCS,
National Cancer Institute, Aviano, Italy; 4Department of Medical Oncology, CRO–IRCCS, National Cancer Institute,
Aviano, Italy; 5Department of Epidemiology, CRO–IRCCS, National Cancer Institute, Aviano, Italy; 6Department of
Radiation Oncology, CRO–IRCCS, National Cancer Institute, Aviano, Italy
ABSTRACT
Background. Organ preservation strategies are under
investigation for patients with locally advanced rectal
cancer (LARC) who achieve a complete pathologic
response in the primary tumor (ypT0) after neoadjuvant
chemoradiation therapy (CRT). This study explored the
value of this approach for cN? patients.
Methods. Data were retrieved from our institutional
prospective rectal cancer database. Tumors with mesorectal
lymph nodes larger than 5 mm shown on endorectal ultra-
sonography, pelvic magnetic resonance imaging, or both
were staged as cN?.
Results. The study population comprised 226 patients
(142 men and 84 women; median age, 64 years) with
LARC who underwent CRT followed by surgery including
total mesorectal excision (TME) (n = 179) and full-
thickness local excision (LE) (n = 47) between 1996 and
2013. At staging, 123 patients (54.4 %) were cN?. In 65
cases (28.7 %), ypCR was observed. Metastatic mesorectal
lymph nodes (ypN?) were detected in 41.6 % of the cN?
patients and in 2.8 % of the cN0 patients (P\ 0.01).
Among the cN? patients, 16 % of the ypT0 cases were
ypN? compared with 51.8 % of the no-ypT0 cases
(P\ 0.01). Among the cN? patients who underwent TME,
the 5-year disease-specific survival (DSS) and disease-free
survival (DFS) rates were respectively 100 and 91.6 % for
the ypT0 patients compared with 71.2 and 58.0 % for the
no-ypT0 patients (P = 0.01). Among the ypN? patients,
the 5-year DSS and DFS rates were both 100 % for the
ypT0 cases compared with 59.1 and 43.3 % for the no-
ypT0 patients. Among the cN? and ypT0 patients, the
5-year DSS and DFS were respectively 100 and 85.7 % for
the TME patients compared with 100 and 91.6 % for the
LE patients. In the multivariate analysis, ypT0 was the only
independent prognostic factor.
Conclusions. Protocols aimed at organ preservation in
LARC that achieve ypT0 after CRT can be offered also to
cN? patients.
Neoadjuvant chemoradiation therapy (CRT) and radical
surgery including total mesorectal excision (TME) reduces the
risk of local recurrence and is considered the standard of care for
patients with locally advanced (T3–4 or any N1–2) mid-distal
rectal cancer (LARC).1–4 A pathologic complete response
(ypCR) shown in the surgical specimen of LARC patients
treated by CRT is observed in up to one-third of the cases.5
In ypCR cases, a favorable long-term oncologic out-
come has been observed,6–9 and organ preservation
strategies including transanal full-thickness local excision
and/or close observation are being explored in patients
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displaying clinical or pathologic complete response to
CRT. This would lead to a reduction in surgery-related
morbidity and mortality and to quality-of-life
improvement.10–23
The potential presence of metastatic mesorectal lymph
nodes, with the related risk of local and distant recurrences,
represents a key limiting factor for the application of organ
preservation strategies. The reported rate of metastatic
mesorectal lymph nodes in the surgical specimen of LARC
patients achieving a complete pathologic response (ypT0)
in the primary tumor is variable,24–33 and the accuracy of
lymph node status restaging after CRT is low.34–36
Because a priori knowledge of pathologic and oncologic
outcome risks is an important issue for protocol design and
for clinician–patient communication at clinical study
enrollment, we specifically focused this study on patients
with rectal cancer staged by endorectal ultrasonography
(EUS), pelvic magnetic resonance imaging (MRI), or both
as having metastatic mesorectal lymph nodes at their initial
diagnosis (cN?).
To evaluate whether cN? patients could be reasonably
eligible for treatment strategies aimed at organ preservation,
we analyzed the pathologic and long-term oncologic out-
comes for LARC patients treated by neoadjuvant CRT at our
institution during a 17-year period.
METHODS
All consecutive informed-consent patients treated by
neoadjuvant CRT and surgery for LARC between January
1996 and October 2013 were identified from our institu-
tional, prospectively maintained, rectal cancer database.
Patients with synchronous distant metastasis were excluded
from the study.
All the patients had biopsy-proven adenocarcinoma of
the rectum. The distance of the tumor from the anal verge
was measured by rigid rectoscopy. Pre- and post-CRT
primary tumor and nodal stagings were evaluated by EUS,
pelvic MRI, or both. Lymph nodes 5 mm or larger were
considered positive. In cases with discrepancy between the
two imaging techniques, the higher stage was considered.
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FIG. 1 Kaplan-Meier estimates for disease-specific survival (a) and
disease-free survival (b) according to a complete pathologic response
of the primary tumor (ypT0) in 123 cN? rectal cancer patients treated
by neoadjuvant chemoradiation followed by total mesorectal excision
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FIG. 2 Kaplan-Meier estimates for disease-specific survival (a) and
disease-free survival (b) according to a complete pathologic response
of the primary tumor (ypT0) in 47 ypN? rectal cancer patients treated
by neoadjuvant chemoradiation followed by total mesorectal excision
(TME) surgery
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Treatment
Preoperative CRT Preoperative CRT was administered
according to several preoperative sequential treatment
protocols developed at our institution, including a
5-fluorouracil (5-FU) bolus ? leucovorin (LV) and 45 Gy
with or withut adjuvant 5-FU/LV, raltitrexed and
50.4 ? 10 Gy of intraoperative radiation therapy (IORT),
capecitabine and 50.4 Gy, continuous infusion
5-FU ? gefitinib and 50.4 ? 10 Gy IORT, and
TABLE 1 Long-term oncologic outcome according to clinocopathologic characteristics in locally advanced rectal cancer patients treated by
neoadjuvant chemoradiation
Variable Total 5-yrs DSS 5-yrs DFS 5-yrs LRFS
n (%) % P Value % P Value % P Value
Sex
Female 84 (37.2) 80.2 0.638 69.9 0.461 89.7 0.042
Male 142 (62.8) 84.4 65.1 78.0
Age (years)
B65 128 (56.6) 82.2 0.863 67.5 0.896 82.8 0.874
[65 98 (43.4) 84.0 65.9 82.1
cN status
cN0 103 (45.6) 86.3 0.537 69.7 0.537 83.0 0.872
cN? 123 (54.4) 80.5 64.2 82.2
Type of surgery
TME 179 (79.2) 81.8 0.201 66.4 0.700 84.0 0.312
LE 47 (20.8) 87.2 68.2 76.8
ypT status
ypT0 65 (28.7) 94.5 0.005 87.3 \0.001 90.5 0.034
No ypT0 161 (71.3) 78.4 58.8 79.3
ypN status 66.2 80.9
ypN0 132 (73.8) 88.0 0.002 72.2 0.008 85.4 0.309
ypN? 47 (26.2) 71.7 55.7 85.7
DSS disease-specific survival, DFS disease-free survival, LRFS local-recurrence-free survival, cN clinical lymph node, TME total mesorectal
excision, LE local excision, ypT0 complete pathologic response in the primary tumor, ypN pathologic lymph node status (only TME patients)
TABLE 2 Metastatic lymph node rates in locally advanced rectal cancer with complete pathologic response in the primary tumor (ypT0)
achieved after neoadjuvant chemoradiation
No. of patients Examined lymph nodes median (range) YpT0 YpN?
N % N %
Read et al.24 644 13 ± 8 42 6.52 1 2.38
Pucciarelli et al.25 235 9 (0–38) 56 23.83 1 1.79
Hughes et al.26 130 6 (0–21) 23 17.69 4 17.39
Guillem and Minsky27 188 9 (0–38) 37 19.68 1 2.70
Berho et al.28 86 13,1 (1–59) 18 20.93 2 11.11
Yeo et al.29 333 (all ypT0) 10 (0–78) 333 100 29 8.70
Jang et al.30 830 11 91 10.96 6 6.59
Tranchart et al.31 245 24 (3–60) 26 10.61 2 7.69
Park et al.32 725 11 (6–15) 143 19.72 13 9.09
Sprenger et al.33 398 28.0 ± 13.7 40 10.0 4 10.00
Current study 179 13 (2–37) 40 22.34 4 10.00
ypT0 complete pathologic response in the primary tumor, ypN pathologic lymph node status
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capecitabine ± oxaliplatin and 50.4 Gy. The radiotherapy
(RT) clinical target volume (CTV2) included the primary
tumor, the mesorectum, and internal iliac lymph nodes. A
second clinical target volume (CTV1) included the
mesorectum corresponding to the primary tumor with a
2-cm radial margin. The RT fractionation was
180 cGy/day, 5 fractions per week. More details on RT
technique and dose prescription have been reported
previously.8
Surgery The patients underwent surgery 6–8 weeks after
completion of neoadjuvant CRT. The surgical procedures
included abdominoperineal resection (APR), low anterior
resection (LAR), and full-thickness transanal local excision
(LE). Radical resection was performed according to TME
principles. Reasons for the use of LE included medical
comorbidity and patient refusal of APR for low-lying
tumors not eligible for coloanal reconstruction due to
anticipation of poor sphincter function.
In more recent years, patients with a major clinical
response to CRT were offered the option of LE in a
prospective clinical study investigating the outcome of LE
after a complete clinical and pathologic response. In these
cases, LE was used to assess the pathologic response in the
primary tumor. Medically fit patients showing no complete
or almost complete pathologic response in the primary
tumor (TRG1 and TRG2 according to Mandard tumor
response grading)37 underwent subsequent TME surgery.
After surgical resection, IORT to a high risk area (presacral
region) was administered according to study protocols, as
mentioned earlier.
Postoperative Chemotherapy Adjuvant 5-FU-based
chemotherapy was administered according to the study
protocol, or in selected cases included patients with
metastatic lymph nodes.
Pathology
Pathologic tumor staging was performed according to
the guidelines of the American Joint Committee on Cancer
and the College of American Pathologists.38 Patients with
no residual cancer cells in the surgical specimen were
considered pathologic complete responders (ypCR).
Follow-up Evaluation
Postoperatively, the patients were examined at follow-
up visits every 3 months for the first 2 years and half-
yearly thereafter. At each follow-up control visit, the CEA
level was determined. Abdominal and pelvic computed
tomography (CT) scan or liver ultrasound and chest x-ray
were performed alternatively every 3–6 months. Colono-
scopy was performed yearly.
Statistical Analysis
The Chi square test or Fisher’s exact test was used to
compare percentages between complete responders and
non-complete responders, and the Wilcoxon rank test was
used for median age comparison. Cumulative probabilities
of overall survival (OS), disease-specific survival (DSS),
disease-free survival (DFS), distant metastasis-free survival
(DMFS), and local recurrence-free survival (LRFS) were
estimated by Kaplan–Meier survival methods,39 and dif-
ferences between subgroups were assessed using the log-
rank test. The duration of follow-up evaluation was cal-
culated as the time from surgery to the event of interest.
Patients without event were censored at the date of the last
follow-up visit. In cases with local and distant metastasis,
both events were recorded and computed at any time of
occurrence. For better assessment of the oncologic impli-
cations of ypCR, the Cox proportional hazards model was
used to adjust the hazard ratios (HRs) and corresponding
95 % confidence intervals (CIs).40 Due to the limitation of
sample size and number of events, only three variables
were entered into the multivariate model: cNstage (cN0 vs
cN1), type of surgery (TME vs LE), and ypT0 (yes vs no).
Collinearity between variables was excluded by means of
the Chi square test. A P value of 0.05 or lower was con-
sidered statistically significant (two-tailed). The SAS
System 9.2 (SAS, Cary, NC, USA) was used as the sta-
tistical software for data analysis.
RESULTS
Patients and Treatment Characteristics
The study population comprised 226 consecutive
patients (142 men and 84 women; median age, 64 years;
range, 25–87 years) with mid-distal LARC and no distant
metastasis treated by neoadjuvant CRT followed by sur-
gery at our institution between January 1996 and October
2013.
At the initial evaluation, 226 patients were staged as
follows: 5 cT2N1 (2.2 %), 79 cT3N0 (34.9 %), 104 cT3N1
(46 %), 12 cT4N0 (5.3 %), 13 cT4N1 (5.7 %), 2 cTxN0
(0.8 %), and 1 cTxN1 (0.4 %). In addition, 10 very low-
lying cT2N0 tumors (4.4 %) were considered at high risk
for recurrence, treated by neoadjuvant CRT, and included
in this study. The median distance of the tumor from the
anal verge was 5 cm (range, 1–12 cm). The total RT dose
was 45 Gy for 42 patients (18.5 %), 50.4 Gy for 180
patients (79.6 %), and 25 Gy for 4 patients (1.7 %). Total
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mesorectal excision was performed for 179 patients (79 %)
(142 LAR and 37 APR), whereas LE was performed for 47
patients (21 %). The documented reasons for the use of LE
were preference after a major clinical response in 22 cases,
patient absolute refusal of APR in 4 cases, and medical
comorbidity in 3 cases. The remaining 18 patients were
enrolled in the prospective clinical study investigating the
outcome for LE after complete clinical and pathologic
response. All patients restaged as ycN? (n = 24) under-
went TME surgery. Intraoperative radiation therapy was
applied in the context of clinical studies. Postoperative
chemotherapy was administered to all 33 ypN? patients
(14 %).
Clinical and Pathologic Response
In the entire patient population, a complete pathologic
response in the primary tumor (ypT0) was observed in 65
cases (28.7 %). For the 179 patients who underwent TME,
the ypCR rate (ypT0N0) was 20.1 % (n = 36). The median
number of examined lymph nodes was 13 (range, 2–37).
Metastatic lymph nodes (ypN?) were found in 47 (26.2 %)
of the surgical specimens: in 4 (10 %) of 40 ypT0 cases, in
1 (9 %) of 11 ypT1 cases, in 12 (21 %) of 57 ypT2 cases,
in 28 (43 %) of 65 ypT3 cases, and in 2 (33.3 %) of 6 ypT4
cases.
Among the patients who underwent TME surgery,
metastatic lymph nodes (ypN?) were detected in 45
(41.6 %) of 108 cN? patients compared with 2 (2.8 %) of
71 cN0 patients (P\ 0.01).
In the subgroup of cN? tumors with ypT0 treated by
TME surgery, 4 (16 %) of 25 (all restaged as ycN0) were
ypN? compared with 43 (51.8 %) of 83 cases that had no
ypT0 (P\ 0.01).
In the subgroup of cN0 tumors with ypT0 treated by
TME surgery, 0 of 15 were ypN? compared with 2 (3.5 %)
of 56 no-ypT0 cases.
At restaging after CRT, comparing ycN status with ypN
status, metastatic lymph nodes at pathology were detected
in 9 of 23 ycN? cases and in 10 of 25 ycN0 cases (sen-
sitivity, 0.47; specificity, 0.51).
Recurrence and Survival
No postoperative mortality occurred. During a median
follow-up period of 48 months, 20 patients (8.84 %)
experienced local recurrence only, 14 (6.19 %) experi-
enced local recurrence and distant metastasis (9 liver, 4
lung and 1 other site cases), and 34 (15.04 %) experienced
distant metastasis only (15 liver, 9 lung, 7 liver and lung,
and 3 multiple-site cases).
In the comparison of ypCR-patients (ypT0N0) and no-
ypCR patients who underwent TME surgery, the 5-year
DSS was respectively 91.0 and 79.4 % (P = 0.029), and
the 5-year DFS was 84.9 and 61.7 % (P = 0.011).
In the entire patient population, the 5-year survival rates
were 79.2 % for OS, 83.0 % for DSS, 66.9 % for DFS,
77.1 % for DMFS, and 82.6 % for LRFS. In the subset of
65 ypT0 patients, 2 (3.1 %) experienced local recurrence
only, 3 (4.61 %) experienced local recurrence and distant
metastasis, and 3 (4.61 %) experienced distant metastasis
only (1 liver, and 2 liver and lung cases).
In the comparison of ypT0 patients (n = 65) with no-
ypT0 patients (n = 161), the 5-year OS was respectively
89.4 versus 75.3 % (P = 0.005), the 5-year DSS was 94.5
versus 78.4 % (P = 0.005), the 5-year DFS was 87.3
versus 58.8 % (P\ 0.001), the 5-year DMFS was 93.0
versus 70.6 % (P = 0.002), and the 5-year LRFS was 90.5
versus 79.3 % (P = 0.034). According to the clinical
lymph node status at initial diagnosis, the 5-year DSS and
DFS were respectively 80.5 and 64.2 % in cN? cases
compared with 86.3 and 69.7 % in cN0 cases (nonsignifi-
cant difference) (Table 1).
Among the cN? patients (n = 123) the 5-year DSS and
DFS were respectively 100 and 91.6 % for the ypT0
patients compared with 71.2 and 58.0 % for the no-ypT0
patients (P\ 0.01; Fig. 1). The 5-year DSS and DFS were
both 100 % for the 4 ypT0N? patients compared with 59.1
and 43.3 % respectively for the 43 no-ypTN? patients
(nonsignificant difference; Fig. 2).
Among the cN? patients who achieved ypT0, the 5-year
DSS and DFS were respectively 100 and 85.7 % for the
TME patients (n = 108) compared with 100 and 91.6 %
for the LE patients (n = 15) (nonsignificant difference). In
the multivariate analysis, ypT0 was the only independent
prognostic factor for DSS (HR, 0.13; 95 % CI, 0.03–0.58;
P = 0.007) and for DFS (HR, 0.25; 95 % CI, 0.12–0.54;
P\ 0.001).
DISCUSSION
The current study investigated whether LARC patients
initially staged as cN? and achieving ypT0 after neoad-
juvant CRT are potential candidates for organ-preserving
surgical strategies. To this end, the rate of ypT0, the inci-
dence of metastatic lymph nodes, and the long-term
oncologic outcome were analyzed in relation to cN status
in LARC patients treated by neoadjuvant CRT and
prospectively followed up at a single institution.
For our patients treated with TME surgery after CRT,
ypCR was achieved in 20.1 % of the cases, which is in line
with the majority of studies previously reported in the lit-
erature.5 Our survival analysis supported the evidence of a
favorable long-term oncologic outcome for patients dis-
playing ypCR. In our series comparing ypCR patients with
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no-ypCR patients, the 5-year DFS rates were respectively
84.9 and 61.7 %. This is in line with the data reported by
Maas et al.9 from a pooled analysis of 3105 LARC patients
treated by preoperative CRT who showed a 5-year DFS of
83.3 % for ypCR patients compared with 65.6 % for no-
ypCR patients. Similarly in a meta-analysis by Zorcolo
et al.41 of 12 studies including 1913 LARC patients, the
5-year DFS was 86.9 % for ypCR patients compared with
63.9 % for no-ypCR patients. Recently Wasmooth et al.42
reported a 5-year DFS of 81 % for patients with ypCR and
50 % for patients without ypCR among 1384 patients
enrolled in the national population-based colorectal cancer
registry of Norway who had advanced T3 and T4 rectal
cancer with N0-2,M0 managed by neoadjuvant long-course
(chemo)radiation. Interestingly, ypCR was associated with
a low risk of metastasizing.
In our subset of ypT0 patients treated by LE surgery, the
local and distant recurrence rates were very low and similar
to those for ypT0 patients treated by TME surgery. This
finding is consistent with data reported by Borshitz et al.,13
who analyzed seven studies reporting oncologic outcome
of LE after neoadjuvant CRT for cT2–3 tumors (n = 237).
In their study, ypT0 was noted in 22 % of the cases, and the
5-year LRFS and DMFS were respectively 100 and 96 %.
Similarly, Pucciarelli et al.18 reported that the 3-year LRFS
was 96.9 % for 43 cT3 or low-lying cT2 rectal cancer
patients treated with CRT followed by LE and observation
for the ypT0-1 patients.
In our patients initially staged as cN? and treated with
CRT followed by TME surgery, metastatic lymph nodes at
pathology were detected in 42.2 % of the cases. However,
in the subgroup of patients with ypT0, metastatic lymph
nodes were detected in 16 % of the surgical specimens.
The rate of metastatic lymph nodes in LARC achieving
ypT0 after CRT has been reported to vary between 2 and
17 %, which is in line with our findings of a 10 % rate
(Table 2).24–33
The assessment of response to treatment is becoming
increasingly important in view of a personalized surgical
approach. Among our patients, restaging accuracy using
standard MRI and endorectal ultrasound was very low.
This is in line with two recent meta-analysis leading to the
conclusion that overall accuracy of restaging is not suffi-
ciently consistent for clinical application.34,35 In addition, a
nomogram using clinicopathologic parameters to predict
ypN status after CRT developed in a training cohort of 891
LARC patients has been shown to achieve an accuracy of
0.77 in an external validation cohort of 258 patients.36
In view of the aforementioned limitations, even if sur-
gical complications, including suture dehiscence and
endoanal pain, are not uncommon among patients under-
going LE after CRT, as previously reported by us and
others,18,43 this remains a procedure of investigational
interest to confirm potential ypT0 status of patients with a
major clinical response. On the other hand, a more con-
servative approach such as the ‘‘wait and see’’ option might
be considered for patients with a complete clinical
response.44 Hopefully, new techniques such as the fluo-
rodeoxyglucose (FDG)-positron emission tomography
(PET) scan and perfusion MRI might lead to a precise
assessment of response.45–48
This study was limited by its single-center retrospective
design and its small number of ypT0 patients displaying
metastatic lymph nodes at pathology. In addition, the large
time frame considered might have accounted for our rela-
tively high local recurrence rate compared with the results
of prospective clinical studies.
In conclusion, our findings indicate that treatment proto-
cols aimed at organ preservation in rectal cancer achieving
ypT0 after CRT can be offered also to patients with clinically
positive mesorectal lymph nodes at their initial diagnosis.
The favorable long-term outcome for ypT0 tumors and the
risk of metastatic mesorectal lymph nodes should be dis-
cussed in patient–clinician communication.
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